COVID-19 Medical Products Supply Chain Week in Review – June 2021 #5

Last week, the FDA added new heart health risk information to mRNA vaccines’ fact sheets. In addition, the U.S. seized unauthorized COVID-19 drugs en route from Bangladesh and India to Mexico. Please see details for these and other supply chain developments below:

  • On June 23, the Wall Street Journal reported that the U.S. government had seized at U.S. airports unauthorized versions of the COVID-19 treatment remdesivir, which were en route from Bangladesh and India to Mexico.
  • On June 24, the FDA issued an emergency use authorization (EUA) for Actemra (tocilizumab) for the treatment of COVID-19 in hospitalized adults and pediatric patients (2 years of age and older) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
  • On June 24, President Biden announced that 66 percent of all American adults have received at least one shot of COVID-19 vaccine, including over 150 million Americans fully vaccinated.
  • On June 25, the FDA announced revisions to the patient and provider fact sheets for the Moderna and Pfizer/BioNTech COVID-19 vaccines to include information regarding risks of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the tissue surrounding the heart) following vaccination.

[View source.]

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Alston & Bird | Attorney Advertising

Written by:

Alston & Bird
Contact
more
less

Alston & Bird on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.